Current preventive treatment for recurrence after curative hepatectomy for liver metastases of colorectal carcinoma: A literature review of randomized control trials

Table 1 Randomized series of adjuvant intrahepatic arterial chemotherapy after surgical resection of hepatic metastases

Authors	Treatment protocol	Sample size(Tx/Ctl)	Observationtime	DFS Tx vs Ctl	OS Tx vs Ctl	Conclusions
Lygidakis et al[8]	Surgery+HAI chemoimmunotherapy	40 (20/20)	3 yr	NA	Median 20 vs	Beneficial
	vs surgery alone				11 (mo) (P < 0.05)
Asahara et al[9]	Surgery+HAI chemotherapy	38 (10/28)	NA	NA	3-yr 100% vs 60%	Beneficial
	vs surgery alone				4-yr 100% vs 47%,
					respectively (P < 0.05)
Rudroff et al[10]	Surgery+HAI 5-FU/MMC	30 (14/16)	5 yr	5-yr 15% vs	5-yr 25% vs 31%	Not
	vs surgery alone			23% (P>0.05)	(P > 0.05)	beneficial
Lorenz et al[11]	Surgery+HAI 5-FU/LV	226 (113/113)	NA	Median 14.2 vs	Median 34.5 vs	Not
	vs surgery alone			13.7 (mo) (P>0.05)	40.8 (mo) (P > 0.05)	beneficial
Kemeny et al[12]	Surgery+HAI FUDR/DEXA+IV	156 (74/82)	2 yr	2-yr 57% vs 42%	2-yr 86% vs 72%	Beneficial
	5-FU/LV vs surgery+IV 5-FU/LV			(P = 0.07)	(P = 0.03)
Tono et al[13]	Surgery+HAI 5-FU+oral 5-FU	19 (9/10)	62.2 (mo)	1-, 2-, 3-yr 77.8%,	1-, 2-, 3-yr 88.9%,	Beneficial
	vs surgery+oral 5-FU		(mean)	77.8%, 66.7% vs	77.8%, 77.8% vs
				50.0%, 30.0%, 20.0%	100.0%, 50.0%, and
				respectively (P = 0.045)	50.0% respectively
					(P = 0.2686)
Kemeny et al[14]	Surgery+HAI FUDR+IV 5-FU	109 (53/56)	NA	4-yr 46% vs 25%	Median 63.7 vs	Beneficial
	vs surgery			(P = 0.04)	49 (mo) (P = 0.60)

Tx: treatment; Ctl: control; DFS: disease-free survival; OS: overall survival; NA: not available.